Halozyme’s ENHANZE® drug delivery technology, which is a proprietary, validated rHuPH20 enzyme paired with our unparalleled expertise in subcutaneous (SC) drug development, has been well-proven to enable rapid, high-volume subcutaneous delivery of co-administered drugs.
Solutions and Benefits
ENHANZE® has facilitated the subcutaneous administration of therapeutics and extended the dosing interval of existing SC drugs.
Learn More
Partnered Products
ENHANZE® is used in 8 co-administered commercial products in 100+ countries with tens of billions of dollars in commercial revenue.
Learn More
Framework for Success
Leverage Halozyme’s approved API and formulation, regulatory, and clinical experience to enable rapid entry into Phase 1 in as fast as 3 months.
Learn More